Apotex Health Corp. and several investors pulled in C$1.3 billion ($932 million) through a Toronto listing, marking the largest Canadian IPO since 2021. The move signals robust appetite for pharmaceutical stocks in a market that has seen sparse large‑scale debuts.

The capital raise provides Apotex with a substantial growth buffer, potentially accelerating its pipeline development and expanding market reach. Investors see the company’s drug portfolio and cost‑efficient manufacturing as attractive in a sector dominated by high R&D spend.

Toronto’s exchange now hosts a broader spectrum of life‑science firms, hinting at a shift toward health‑tech innovation in Canadian capital markets. The IPO’s size also pressures competitors to reevaluate their own funding strategies.

The transaction underscores a trend of Canada’s pharma sector gaining traction with public markets, offering a template for future listings in the industry.